Among 293,872 UK Biobank participants without baseline cardiovascular disease or lipid-lowering therapy, HDL-C retained an inverse association with incident ASCVD after accounting for apoB and triglycerides. The observational findings do not establish a protective biological effect.

Among 49,440 adults identified as Arab American in a Texas health system, 15.2% had documented ASCVD and 3.4% met the study’s premature-disease definition. Identification methods and encounter-based age classification limit interpretation.

Among 45,949 patients undergoing coronary revascularization, high-intensity statin therapy was associated with fewer recurrent cardiovascular events and deaths over a median six years. The retrospective analysis did not establish causality or an optimal LDL-C threshold.

A manufacturer-funded randomized trial involving 61 participants reported improved vascular function markers and lower systolic blood pressure with a multi-ingredient supplement over six months. Cardiovascular event reduction and long-term safety were not established.

In statin-naive adults with coronary artery disease, rosuvastatin plus ezetimibe produced greater LDL-C reduction and coronary plaque regression than atorvastatin over 18 months. Whether the imaging differences translate into fewer cardiovascular events remains uncertain.

A secondary analysis of CARBFUNC found divergent lipid responses to a very-low-carbohydrate, high-saturated-fat diet in adults with obesity. ApoB remained largely unchanged despite higher LDL-C, while long-term cardiovascular outcomes remain unresolved.